30 June 2021

Invasive pulmonary aspergillosis (IPA) is increasingly reported in patients with severe coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU). Therefore, Paul Verweij, theme Infectious diseases and global health, and colleagues set a goal to develop practical guidelines for the diagnosis and management of COVID-19 associated pulmonary aspergillosis (CAPA). This taskforce report is recently published in Intensive Care Medicine. 

Methods

A group of 28 international experts reviewed current insights in the epidemiology, diagnosis and management of CAPA and developed recommendations using GRADE methodology.

Results

The prevalence of CAPA varied between 0 and 33%, which may be partly due to variable case definitions, but likely represents true variation. Bronchoscopy and bronchoalveolar lavage (BAL) remain the cornerstone of CAPA diagnosis, allowing for diagnosis of invasive Aspergillus tracheobronchitis and collection of the best validated specimen for Aspergillus diagnostics. Most patients diagnosed with CAPA lack traditional host factors, but pre-existing structural lung disease and immunomodulating therapy may predispose to CAPA risk. Computed tomography seems to be of limited value to rule CAPA in or out, and serum biomarkers are negative in 85% of patients. As the mortality of CAPA is around 50%, antifungal therapy is recommended for BAL positive patients, but the decision to treat depends on the patients' clinical condition and the institutional incidence of CAPA. We recommend against routinely stopping concomitant corticosteroid or IL-6 blocking therapy in CAPA patients.

Conclusion

CAPA is a complex disease involving a continuum of respiratory colonization, tissue invasion and angioinvasive disease. Knowledge gaps including true epidemiology, optimal diagnostic work-up, management strategies and role of host-directed therapy require further study.

read more

Related news items


Rubicon grants awarded to three RIMLS researchers

19 April 2022

Three researchers have received Rubicon funding from NWO/ZonMw. This will enable Elke Muntjewerff, Laura de Vries and Laurens van de Wiel to do research at a foreign research institute for the next two years.

read more

Poster prize for Valerie Betting

12 April 2022

At the recent EMBO Workshop PIWI proteins and piRNAs, Valerie Betting, theme Infectious Diseases & Global Health, won a poster prize for her poster Elucidating the role of Yb in PIWI4/tapiR-mediated gene silencing.

read more

Neolithic made us taller and more intelligent, but more prone to heart disease How modern European populations have evolved over the past 50,000 years

6 April 2022

After the Neolithic, European populations showed an increase in height and intelligence, reduced skin pigmentation and increased risk of cardiovascular disease due to genetic changes that lowered concentrations of 'good' HDL cholesterol.

read more

Immunogenetic studies in diverse populations are essential Clear immunological differences between populations in Europe and Africa

15 February 2022

Genetic factors that partly determine host defenses sometimes differ significantly between people and populations. This is shown in a publication in the American Journal of Human Genetics by researchers from the Netherlands, Tanzania and India.

read more

What does the shingles vaccine teach us about other vaccines? Investigating the role of trained immunity

27 January 2022

The vaccine for shingles, a condition that causes itching, pain, and blisters, is 90% effective, even in elderly. This is remarkable, since most vaccines offer less protection in elderly. Radboudumc is investigating why this vaccine works so well and how it might help us to develop better vaccines.

read more